MBL Wealth
CORT icon

MBL Wealth’s Corcept Therapeutics CORT Stock Holding History

MBL Wealth’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$343K Buy
+2,977
New +$320K 0.02% 427

Other funds holding CORT

Ingalls & Snyder LLC
Ingalls & Snyder LLC New York $3.91B AUM 60.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

MBL Wealth's CORT Position: Q3 2026 in Review

MBL Wealth opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 2,977 shares worth $343K. The stake represents 0.02% of the portfolio and ranks #427 among its holdings.

362 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • MBL Wealth held 2,977 shares of Corcept Therapeutics worth $343K as of Q3 2026.
  • Corcept Therapeutics was a new MBL Wealth position in Q3 2026.
  • Corcept Therapeutics made up 0.02% of MBL Wealth's portfolio in Q3 2026, its #427 holding.
  • 362 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on MBL Wealth's 13F filing for Q3 2026, filed 22 Oct 2026.